27 Oct 2020 14:24
Tuesday, 27 October 2020
Dechra® Pharmaceuticals PLC
Results of Annual General Meeting (AGM)
A poll was held on each of the resolutions proposed at the Annual General Meeting (AGM) of the Company held today
(27 October 2020). All resolutions were passed and are as follows:
Resolution (No. as noted on proxy form)
| Total For (includes Discretionary) | Total Against | Total Cast (excludes Withheld) | Withheld (1) | |||
No. of votes | % of vote | No. of votes | % of vote | No. of votes | % of vote | No. of votes | |
Ordinary Business: | |||||||
Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report
| 80,530,666 | 99.77% | 182,733 | 0.23% | 80,713,399
| 74.67% | 907,133 |
Resolution 2: To approve the Directors' Remuneration Report
| 81,088,589 | 99.36% | 524,975 | 0.64% | 81,613,564 | 75.51% | 6,968 |
Resolution 3: To receive and approve the Directors' Remuneration Policy
| 74,112,644 | 90.81% | 7,501,119 | 9.19% | 81,613,763 | 75.51% | 6,768 |
Resolution 4: To declare a final dividend
| 81,611,953 | 99.99% | 8,079 | 0.01% | 81,620,032 | 75.51% | 500 |
Resolution 5: To elect Paul Sandland
| 80,408,925 | 98.52% | 1,208,931 | 1.48% | 81,617,856 | 75.51% | 2,676 |
Resolution 6: To elect Alison Platt
| 80,875,757 | 99.09% | 742,099 | 0.91% | 81,617,856 | 75.51% | 2,676 |
Resolution 7: To re-elect William Anthony Rice
| 71,921,431 | 88.82% | 9,050,362 | 11.18% | 80,971,793 | 74.91% | 648,739 |
Resolution 8: To re-elect Ian Page
| 80,588,170 | 98.74% | 1,028,236 | 1.26% | 81,616,406 | 75.51% | 4,126 |
Resolution 9: To re-elect Anthony Griffin
| 80,588,674 | 98.74% | 1,027,732 | 1.26% | 81,616,406 | 75.51% | 4,126 |
Resolution 10: To re-elect Lisa Bright
| 72,640,656 | 89.00% | 8,975,750 | 11.00% | 81,616,406 | 75.51% | 4,126 |
Resolution 11: To re-elect Julian Heslop
| 80,122,785 | 98.17% | 1,492,511 | 1.83% | 81,615,296 | 75.51% | 5,236 |
Resolution 12: To re-elect Ishbel Macpherson
| 80,238,227 | 98.31% | 1,379,629 | 1.69% | 81,617,856 | 75.51% | 2,676 |
Resolution 13: To re-elect Lawson Macartney
| 80,129,006 | 98.18% | 1,487,380 | 1.82% | 81,616,386 | 75.51% | 4,146 |
Resolution 14: To re-appoint PricewaterhouseCoopers as external auditor of the company
| 81,607,914 | 99.99% | 11,668 | 0.01% | 81,619,582 | 75.51% | 950 |
Resolution 15: To authorise the Audit Committee to determine the remuneration of the external auditor
| 81,616,178 | 100.00% | 2,944 | 0.00% | 81,619,122 | 75.51% | 1,410 |
Special Business: | |||||||
Resolution 16: To authorise the directors to allot shares to specific limits
| 76,917,382 | 94.24% | 4,701,513 | 5.76% | 81,618,895 | 75.51% | 1,637 |
Resolution 17: To disapply the pre-emption rights
| 81,554,619 | 99.92% | 63,753 | 0.08% | 81,618,372 | 75.51% | 2,160 |
Resolution 18: To disapply additional pre-emption rights
| 80,907,507 | 99.13% | 710,766 | 0.87% | 81,618,273 | 75.51% | 2,259 |
Resolution 19: To authorise the Company to purchase its own shares
| 79,915,307 | 98.15% | 1,509,708 | 1.85% | 81,425,015 | 75.33% | 195,517 |
Resolution 20: To authorise the Company to hold any general meeting (other than an AGM) on not less than 14 clear days' notice
| 80,053,146 | 98.08% | 1,566,747 | 1.92% | 81,619,893 | 75.51% | 639 |
Notes:
1. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.
2. Resolutions 1 to 16 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.
3. Resolutions 17 to 20 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.
4. Issued Share Capital at meeting date: 108,089,861.
5. Equiniti, Registrar to the Company, were appointed for the purpose of the Poll taken at the AGM and certify as scrutineer that the result of the Poll is correctly set out above.
In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at the FCA document viewing facility https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
For further information, please contact:
Melanie Hall
Company Secretary
Dechra Pharmaceuticals PLC
Telephone: +44 (0) 1606 814 730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.